Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.470
+0.010 (0.68%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Pliant Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
171
Market Cap
90.24M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
PLRX News
- 21 days ago - Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference - GlobeNewsWire
- 25 days ago - Pliant Therapeutics: An Activist On Deck - Seeking Alpha
- 6 weeks ago - Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - GlobeNewsWire
- 6 weeks ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - PRNewsWire
- 6 weeks ago - Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement - GlobeNewsWire
- 2 months ago - Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder - Benzinga
- 2 months ago - Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis - GlobeNewsWire